Rna Diagnostics Inc. appoints Dr. Matthew P. Goetz to Clinical Advisory Board

By |July 6th, 2017|

 

Rna Diagnostics Inc. announced today that Dr. Matthew P. Goetz, Consultant and Professor at Mayo Clinic, Rochester, MN has been appointed to the company’s Clinical Advisory Board (CAB).

“Dr. Goetz brings a wealth of scientific knowledge and clinical trial experience in breast cancer to Rna Diagnostics,” […]

Comments Off on Rna Diagnostics Inc. appoints Dr. Matthew P. Goetz to Clinical Advisory Board

Rna Diagnostics Launches BREVITY – International Validation Trial of RDA™ in Breast Cancer

By |June 14th, 2017|

Rna Diagnostics announced the launch of an international prospective clinical trial to validate the RNA Disruption Assay™ (RDA™) as a tool for treatment management of primary breast cancer. BREVITY (Breast Cancer Response EValuation for Individualized TherapY) will include 500+ patients with invasive breast cancer, scheduled […]

Comments Off on Rna Diagnostics Launches BREVITY – International Validation Trial of RDA™ in Breast Cancer

Further evidence RDA™ may predict clinical outcome of chemotherapy in Journal of the National Cancer Institute

By |September 15th, 2016|

A new study provides further evidence that the Rna Disruption Assay™ (RDA™) may be a useful tool to predict the clinical outcome of neoadjuvant chemotherapy in breast cancer patients. RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth […]

Comments Off on Further evidence RDA™ may predict clinical outcome of chemotherapy in Journal of the National Cancer Institute

April 2016 Newsletter

By |April 27th, 2016|

April Newsletter 2016
APRIL 27, 2016

In this issue:   an interview with the new CEO, patient accrual updates and more…

Comments Off on April 2016 Newsletter

Rna Diagnostics Inc. appoints Dr. Jeremy Bridge-Cook President and CEO

By |April 1st, 2016|

Rna Diagnostics Inc. appoints
Dr. Jeremy Bridge-Cook President and CEO

Dr. Ken Pritzker, on behalf of the Board of Directors of Rna Diagnostics Inc., is pleased to announce the appointment of Dr. Jeremy Bridge-Cook to the position of President and Chief Executive Officer of Rna Diagnostics Inc. […]

Comments Off on Rna Diagnostics Inc. appoints Dr. Jeremy Bridge-Cook President and CEO

RNA Disruption is a major biologic mechanism induced by multiple classes of chemotherapy drugs

By |March 10th, 2016|

Rna Diagnostics announces the publication of a study on February 24 2016 in the journal BMC Cancer entitled RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines. The study concludes that RNA disruption, as assessed by the RNA Disruption […]

Comments Off on RNA Disruption is a major biologic mechanism induced by multiple classes of chemotherapy drugs

Paul Lucas joins the Board of Directors at Rna Diagnostics Inc.

By |February 18th, 2016|

Rna Diagnostics Inc. announced today that Paul Lucas, an accomplished veteran of the Life Sciences industry, has joined the Company’s Board of Directors.

“Paul brings a wealth of proven business and Life Science innovation insight to Rna Diagnostics,” said Dr. Ken Pritzker, President and CEO of […]

Comments Off on Paul Lucas joins the Board of Directors at Rna Diagnostics Inc.

Rna Diagnostics “Breaking the Mold” at World Cancer Day event hosted by the Ontario Institute for Cancer Research and MaRS

By |February 12th, 2016|

The Ontario Institute for Cancer Research and MaRS Discovery District hosted an event for World Cancer Day under the banner of “Breaking the Mold: Rethinking the Cancer System.” Hosted by André Picard, Health Columnist of The Globe and Mail, the panel consisted of leading Cancer […]

Comments Off on Rna Diagnostics “Breaking the Mold” at World Cancer Day event hosted by the Ontario Institute for Cancer Research and MaRS

Rna Diagnostics announces new study in chemotherapy efficacy in canine lymphoma in partnership with University of Guelph’s Ontario Veterinary College and supported by $100,000 grant from the Ontario Centres of Excellence

By |January 21st, 2016|

Rna Diagnostics Inc announced today a new study to investigate RDA as a predictor for chemotherapy efficacy in canine lymphoma in partnership with University of Guelph Institute for Comparative Cancer Investigation and the Mona Campbell Centre for Animal Cancer at the Ontario Veterinary College. This […]

Comments Off on Rna Diagnostics announces new study in chemotherapy efficacy in canine lymphoma in partnership with University of Guelph’s Ontario Veterinary College and supported by $100,000 grant from the Ontario Centres of Excellence

RDA™ Evolves into Platform Technology

By |November 18th, 2015|

While the primary focus of RNA Disruption Assay (RDA) continues to be breast cancer chemotherapy management, it is rapidly evolving into a platform technology that will be utilized in the management  of  treatments across multiple cancers. RDA is now being employed in clinical trials for […]